MedPath

ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3
Completed
Conditions
Glaucoma
Open-Angle Ocular Hypertension
Interventions
Drug: Bimatoprost SR
Drug: Sham Bimatoprost SR
Procedure: Selective Laser Trabeculoplasty
Procedure: Sham Selective Laser Trabeculoplasty
First Posted Date
2015-12-22
Last Posted Date
2022-02-23
Lead Sponsor
Allergan
Target Recruit Count
144
Registration Number
NCT02636946
Locations
🇺🇸

Wolstan & Goldberg Eye Associates, Torrance, California, United States

🇺🇸

Asheville Eye Associates, Asheville, North Carolina, United States

🇩🇰

Glostrup Hospital, Glostrup, Hovedstaden, Denmark

and more 30 locations

Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects

Phase 1
Completed
Conditions
Renal Function
Interventions
First Posted Date
2015-12-18
Last Posted Date
2018-02-08
Lead Sponsor
Allergan
Target Recruit Count
19
Registration Number
NCT02634437
Locations
🇺🇸

Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States

🇺🇸

Clinical Pharmacology of Miami, Miami, Florida, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

and more 2 locations

A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients

Phase 4
Completed
Conditions
Urinary Incontinence
Overactive Bladder
Interventions
Biological: Botulinum Toxin Type A
First Posted Date
2015-11-10
Last Posted Date
2016-07-21
Lead Sponsor
Allergan
Target Recruit Count
168
Registration Number
NCT02601287
Locations
🇰🇷

Pusan National University Hospital, Busan, Korea, Korea, Republic of

🇰🇷

The Catholic University of Korea Bucheion St. Mary Hospital, Gyeonggi-do, Korea, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Korea, Republic of

and more 2 locations

A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

Phase 2
Completed
Conditions
Presbyopia
Interventions
Drug: AGN-199201 ophthalmic solution
Drug: AGN-190584 ophthalmic solution
Drug: AGN-190584 vehicle
Drug: AGN-199201 + AGN-190584 Combination
Drug: AGN-199201 vehicle
First Posted Date
2015-11-03
Last Posted Date
2020-12-22
Lead Sponsor
Allergan
Target Recruit Count
163
Registration Number
NCT02595528
Locations
🇺🇸

Sall Research Medical Center, Artesia, California, United States

🇺🇸

Milton M. Hom, OD, FAAO, Azusa, California, United States

🇺🇸

WCCT Global, LLC, Costa Mesa, California, United States

and more 17 locations

A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India

Completed
Conditions
Urinary Incontinence
Overactive Bladder
Interventions
Biological: botulinum toxin Type A
First Posted Date
2015-10-29
Last Posted Date
2018-03-26
Lead Sponsor
Allergan
Target Recruit Count
250
Registration Number
NCT02590250
Locations
🇮🇳

Dr. Ram Manohar Lohia Hospital, New Delhi, Delhi, India

🇮🇳

Bodyline Hospitals, Ahmedabad, Gujarat, India

🇮🇳

Fortis Hospitals, Bengaluru, Karnataka, India

and more 9 locations

A Multicenter Prospective Non-Interventional Study Assessing the Management of Canadian Women With Uterine Fibroids

Completed
Conditions
Leiomyoma
Interventions
Other: No Intervention
First Posted Date
2015-10-20
Last Posted Date
2020-02-28
Lead Sponsor
Allergan
Target Recruit Count
1500
Registration Number
NCT02580578
Locations
🇨🇦

Children's and Women's Health Centre of British Columbia - The University of British Columbia, Vancouver, British Columbia, Canada

🇨🇦

Minimally Invasive Gynecology Clinic, London, Ontario, Canada

🇨🇦

Peter Lougheed Centre/University of Calgary, Calgary, Alberta, Canada

and more 17 locations

Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

Phase 4
Completed
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
Interventions
First Posted Date
2015-10-08
Last Posted Date
2018-07-05
Lead Sponsor
Allergan
Target Recruit Count
750
Registration Number
NCT02571712
Locations
🇨🇳

Xuanwu Hospital Capital Medical University, Beijing, Beijing, China

🇨🇳

Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China

🇨🇳

Eye & ENT Hospital of Fudan University, Shanghai, Shanghai, China

and more 12 locations

A Study of Hyaluronic Acid Injectable Gel (VYC-25L) for Restoration and Creation of Facial Volume in the Chin and Jaw

Not Applicable
Completed
Conditions
Chin Retrusion
Interventions
Device: Hyaluronic Acid Injectable Gel
First Posted Date
2015-09-25
Last Posted Date
2017-12-13
Lead Sponsor
Allergan
Target Recruit Count
120
Registration Number
NCT02559908
Locations
🇳🇱

Joost Kroon Cosmetische Kliniek, Amsterdam, Netherlands

🇩🇪

Dermatogische Privatpraxis CentroDerm GmbH, Wuppertal, Germany

🇩🇪

Rosenpark Research Geschäftsbereich der Rosenparkklinik GmbH, Darmstadt, Germany

and more 7 locations

Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

Completed
Conditions
Urinary Bladder, Overactive
Interventions
First Posted Date
2015-09-23
Last Posted Date
2016-09-02
Lead Sponsor
Allergan
Target Recruit Count
315
Registration Number
NCT02557971
Locations
🇺🇸

The Charlotte-Mecklenburg Hospital Authority DBA Carolinas Healthcare System, Charlotte, North Carolina, United States

🇺🇸

University of California, Davis, Davis, California, United States

🇺🇸

Capital Region Urology, Irvine, California, United States

and more 4 locations

A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® for Nasolabial Folds in Chinese Adults

Not Applicable
Completed
Conditions
Nasolabial Fold
Interventions
Device: Restylane®
Device: JUVÉDERM® VOLIFT® with Lidocaine
First Posted Date
2015-09-23
Last Posted Date
2017-08-30
Lead Sponsor
Allergan
Target Recruit Count
175
Registration Number
NCT02558283
Locations
🇨🇳

Peking University Third Hospital, Beijing, China

🇨🇳

General Hospital of Guangzhou Military Command of PLA, Guangzhou, China

🇨🇳

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Guangzhou, China

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath